ABSTRACT
Sequencing data from Plasmodium ovale genotypes co-circulating in multiple countries support the hypothesis that P. ovale curtisi and P. ovale wallikeri are 2 separate species. We conducted a multicenter, retrospective, comparative study in Spain of 21 patients who had imported P. ovale curtisi infections and 14 who had imported P. ovale wallikeri infections confirmed by PCR and gene sequencing during June 2005-December 2011. The only significant finding was more severe thrombocytopenia among patients with P. ovale wallikeri infection than among those with P. ovale curtisi infection (p = 0.031). However, we also found nonsignificant trends showing that patients with P. ovale wallikeri infection had shorter time from arrival in Spain to onset of symptoms, lower level of albumin, higher median maximum core temperature, and more markers of hemolysis than did those with P. ovale curtisi infection. Larger, prospective studies are needed to confirm these findings.
Subject(s)
Malaria/epidemiology , Malaria/parasitology , Plasmodium ovale/classification , Adolescent , Adult , Child , Comorbidity , Female , History, 21st Century , Humans , Malaria/complications , Malaria/diagnosis , Malaria/history , Male , Middle Aged , Plasmodium ovale/genetics , Retrospective Studies , Spain/epidemiology , Thrombocytopenia/diagnosis , Thrombocytopenia/etiology , Young AdultABSTRACT
El tabaquismo es el factor de riesgo cardiovascular modificable más importante. El bupropión es el método de deshabituación tabáquica (DT) más eficaz, pero se metaboliza por el citocromo P-450 y podría provocar interacciones con los antirretrovirales. Presentamos un estudio prospectivo de DT con bupropión en pacientes VIH1 en tratamiento antirretroviral. Se incluyeron 21 pacientes. El 38% seguían sin fumar al año. No se encontraron interacciones clínicamente significativas. La DT con bupropión es efectiva y no ha provocado interacciones clínicamente significativas con los antirretrovirales (AU)
Smoking is the most important modifiable cardiovascular risk factor. Bupropion administration is an effective method to achieve smoking cessation (SC), but the drug is metabolized by the cytochrome P450 enzyme system and this might cause interactions with antiretroviral drugs. We present a prospective study of bupropion SC therapy in HIV-positive patients under antiretroviral treatment. A total of 21 patients were studied; 38% of them stopped smoking for more than one year. No clinically significant drug interactions were found. Bupropion SC therapy was effective in HIV-positive patients and did not cause significant clinical interactions with antiretroviral drugs (AU)
Subject(s)
Humans , Tobacco Use Disorder/drug therapy , Tobacco Use Cessation/methods , Bupropion/pharmacokinetics , HIV Infections , Anti-Retroviral Agents/pharmacokinetics , Drug Interactions , Prospective StudiesABSTRACT
Smoking is the most important modifiable cardiovascular risk factor. Bupropion administration is an effective method to achieve smoking cessation (SC), but the drug is metabolized by the cytochrome P450 enzyme system and this might cause interactions with antiretroviral drugs. We present a prospective study of bupropion SC therapy in HIV-positive patients under antiretroviral treatment. A total of 21 patients were studied; 38% of them stopped smoking for more than one year. No clinically significant drug interactions were found. Bupropion SC therapy was effective in HIV-positive patients and did not cause significant clinical interactions with antiretroviral drugs.
